Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients

INTRODUCTION: New regimens involving direct-acting antiviral agents (DAAs) have recently been approved for the treatment of hepatitis C virus (HCV) genotype 4 (GT4). The current study aims to assess the efficacy and safety of sofosbuvir (SOF) with pegylated interferon (PegINF)/ribavirin (RBV) for ch...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Exp Hepatol
Autori principali: Abdel-Moneim, Adel, Abood, Alaa, Abdel-Gabaar, Mohamed, Zanaty, Mohamed I., Ramadan, Mohamed
Natura: Artigo
Lingua:Inglês
Pubblicazione: Termedia Publishing House 2018
Soggetti:
Original Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6185926/
https://ncbi.nlm.nih.gov/pubmed/30324144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/ceh.2018.78123
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi